Key result
Erythropoietin reduces mortality and improves fractional shortening in rats with doxorubicin-induced cardiomyopathy via enhanced EPCs.
Why the study?
Doxorubicin causes severe cardiotoxicity, and it was hypothesized that endothelial progenitor cells are compromised and that correcting this functional impairment with erythropoietin could attenuate myocardial dysfunction.
Does erythropoietin improve myocardial performance in doxorubicin-induced cardiomyopathy?
Does erythropoietin improve myocardial performance in doxorubicin-induced cardiomyopathy?
Erythropoietin protects against doxorubicin-induced myocardial dysfunction in rats, partially by enhancing endothelial progenitor cell numbers and function.
No takes yet. Share an insight, caveat, or question.
Hypothesis-generating in rat doxorubicin models; should not yet influence clinical practice or trials.
Saher Hamed (2006) studied Doxorubicin-induced cardiomyopathy (n=160). Erythropoietin vs. PBS was evaluated on Fractional shortening and mortality. Erythropoietin treatment improved fractional shortening and reduced mortality in rats with doxorubicin-induced cardiomyopathy, partially mediated by enhanced endothelial progenitor cell function.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: